My understanding is that the main problem with gene therapy is the body's immune response to the vector (delivery vehicle?). That our bodies are set up to recognize foreign material and attack it, especially viruses.
Anyway, and this just my interpretation of what I've read and heard, it sounds like the brit's (uk gene therapy consortium) have developed a vector (non-virus) that doesn't have any cpgs (stuff that signals the body to attack). That they've tested the product on mice and sheep and that it works (on mice and sheep anyway). So my first question is, does anyone know if that is true - that it has corrected cf in animals?
Also, has anyone heard anything new about what copernicus is doing? I heard that the brit's are peer reviewing their work. I thought that was really smart of copernicus (or the foundation) - the collaboration.
In general, I've been very impressed with the foundations approach to drug development. We're currently enrolled in the denufosol trial (both my girls, 5 and 7). Anyone else excited about any of this?
Anyway, and this just my interpretation of what I've read and heard, it sounds like the brit's (uk gene therapy consortium) have developed a vector (non-virus) that doesn't have any cpgs (stuff that signals the body to attack). That they've tested the product on mice and sheep and that it works (on mice and sheep anyway). So my first question is, does anyone know if that is true - that it has corrected cf in animals?
Also, has anyone heard anything new about what copernicus is doing? I heard that the brit's are peer reviewing their work. I thought that was really smart of copernicus (or the foundation) - the collaboration.
In general, I've been very impressed with the foundations approach to drug development. We're currently enrolled in the denufosol trial (both my girls, 5 and 7). Anyone else excited about any of this?